Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 01, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,700,000 ordinary shares of 25 pence each.
- Purchase Price: 1,310.39 pence per share.
- Treasury Holdings: 417,239,158 shares (representing 7.44% of total voting rights).
- Shares in Issue: 5,606,893,100 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 1,700,000 shares on October 1, 2007. These shares are held in Treasury. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (417,239,158) and the percentage of voting rights represented (7.44%).
- Confirm the total number of shares in issue excluding Treasury shares (5,606,893,100) for disclosure threshold calculations.
- Note that this filing is a notification of a share buyback and does not contain operational or financial performance results.